scispace - formally typeset
M

Masahiko Yano

Researcher at Niigata University

Publications -  198
Citations -  4432

Masahiko Yano is an academic researcher from Niigata University. The author has contributed to research in topics: Esophagectomy & Cancer. The author has an hindex of 30, co-authored 198 publications receiving 3547 citations. Previous affiliations of Masahiko Yano include The Nippon Dental University.

Papers
More filters
Journal ArticleDOI

Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.

TL;DR: In this paper, the anti-mouse IL-6 receptor (mIL-6R) antibody was used to prevent muscle atrophy in 16-week-old transgenic mice.
Journal ArticleDOI

A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation

TL;DR: A novel indocyanine green (ICG) fluorescence imaging technique is presented to visualize hepatocellular carcinoma (HCC) and shows clear delineation between tumor and normal tissue.
Journal ArticleDOI

Risk of Recurrence in a Long-term Follow-up After Surgery in 417 Patients With Hepatitis B- or Hepatitis C-Related Hepatocellular Carcinoma

TL;DR: Hepatitis viral type is an independent factor for recurrence of HCC in a long-term clinical follow-up and suggests that a different strategy may need to be used to control postoperative recurrence by the viral types in HCC patients.
Journal ArticleDOI

Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.

TL;DR: In the resected cases, the locoregional control was comparable between patients with PC-R and PC-BR after preoperative CRT, and the survival rate was lower than the rate for those with PCs, due to a higher incidence of peritoneal and distant recurrence in the patients withPC-BR.
Journal ArticleDOI

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

TL;DR: Results of this trial suggest that a combination of preoperative full-dose gemcitabine, concurrent 3D-conformal radiation, surgery, and postoperative LPC is feasible for the treatment of T3-pancreatic cancer.